Number of days in hospital · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Time to complete healing · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Two studies. Median time to total healing was shorter for patients receiving oral or intravenous aciclovir than placebo: median of 8 days versus 21 days, P = 0.01 (Shepp 1985); 13.9 days versus 20.7 days, P = 0.08…
2 studies
GRADE not reported
Recurrence of lesions · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Duration of viral shedding · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Relief of pain · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Amount of analgesia · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Patient quality of life · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Adverse effects · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Intervention not reported
All cause mortality · patients with myelodysplastic syndrome
It is very uncertain whether the intervention changes all cause mortality (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality secondary to bleeding/infection/transfusion reactions or iron overload ‐ not reported · patients with myelodysplastic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life ‐ not reported · patients with myelodysplastic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Frequency and length of hospital admissions ‐ not reported · patients with myelodysplastic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found